With the transfer of sales rights between domestic pharmaceutical companies for major original products expected, the change is expected to affect not only the pharmaceutical and distribution industries but also front-line pharmacies.

According to the pharmaceutical wholesale industry sources on the 13th, the transfer of rights to domestic pharmaceutical companies for some of Viatris and Takeda Pharmaceutical’s products is being confirmed or under discussion in the first quarter of this year.

The products for which the recent transfer of rights has been confirmed and related notices are being issued to the pharmaceutical wholesale industry one after another are: Viatris' Neuront